You are here

A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn

Last updated on May 17, 2019

FOR MORE INFORMATION
Study Location
CHUL du CHU de Quebec
Quebec, , G1V 4G2 Canada
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Familial Persistent Pulmonary Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0-4
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Neonates with persistent pulmonary hypertension of the newborn

- Age =34 weeks gestational age

- Oxygenation Index >15 and

- Concurrent treatment with inhaled nitric oxide and >=50% oxygen

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Prior or immediate need for extracorporeal membrane oxygenation or cardiopulmonary
resuscitation

- Expected duration of mechanical ventilation

- Profound hypoxemia

- Life-threatening or lethal congenital anomaly

NCT01720524
Pfizer
Active, not recruiting
A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now